Evidence map›Paper›PMID 41240139›Full record

ArticleMikrochimica acta2025

Developing FRET-based UCNP@SiO

Yuanhang Li, Xing Wang, Li Yang, Xudong Xie, Shengnan Yao, Tian Min, Zhengjian Qi

Abstract read
PubMed Publisher
In one paragraph

Article in Mikrochimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yuanhang LiSchool of Chemistry and Chemical Engineering, Southeast University, Nanjing, Jiangsu, 211189, PR China.
Xing WangSchool of Chemistry and Chemical Engineering, Southeast University, Nanjing, Jiangsu, 211189, PR China.
Li YangSchool of Chemistry and Chemical Engineering, Southeast University, Nanjing, Jiangsu, 211189, PR China.
Xudong XieSchool of Chemistry and Chemical Engineering, Southeast University, Nanjing, Jiangsu, 211189, PR China.
Shengnan YaoSchool of Chemistry and Chemical Engineering, Southeast University, Nanjing, Jiangsu, 211189, PR China.
Tian MinSchool of Chemistry and Chemical Engineering, Southeast University, Nanjing, Jiangsu, 211189, PR China.
Zhengjian QiSchool of Chemistry and Chemical Engineering, Southeast University, Nanjing, Jiangsu, 211189, PR China. qizhengjian@seu.edu.cn.

Funding

Science and Technology Achievements Transformation Special Fund of Jiangsu Province BA2019052
6 · The paper itself

Abstract

Photodynamic therapy (PDT) has emerged as a promising strategy for cancer treatment due to high spatiotemporal selectivity. However, most of the conventional photosensitizers (as the core component of PDT) are activated by visible light, which suffers from limited tissue penetration, thereby restricting the clinical applications of PDT. In this study, two carboxymethyl-functionalized aggregation-induced emission (AIE) compounds, (E)-2-(4-(bis(4-methoxyphenyl)amino)styryl)-5-carboxy-3-methylbenzo[d]thiazol-3-ium (MOTBAC) and (E)-5-carboxy-2-(2-(5-(4-(diphenylamino)phenyl)thiophen-2-yl)vinyl)-3-methylbenzo[d]thiazol-3-ium (TTBAC), were synthesized and coordinated with upconversion nanoparticles (UCNPs) to form UCNPs-MOTBAC and UCNPs-TTBAC nanoconjugates, which generate reactive oxygen species (ROS) under 980-nm irradiation. The energy transfer efficiencies from UCNPs to MOTBAC and TTBAC were 29.4% and 33.9%, respectively. To enhance TTBAC loading, TTBAC was silanized and covalently grafted onto the UCNPs@mSiO

Indexed as

Antineoplastic AgentsLysosomesNanoparticlesPhotochemotherapyPhotosensitizing AgentsCell SurvivalFluorescence Resonance Energy TransferHeLa CellsHumansInfrared RaysPolyethylene GlycolsReactive Oxygen SpeciesSilicon DioxideAntineoplastic AgentsPhotosensitizing AgentsPolyethylene GlycolsReactive Oxygen SpeciesSilicon DioxideAggregation-induced emissionLysosome targetingPhotodynamic therapyUpconversion nanoparticles

Identifiers

PMID41240139

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.